According to the latest report by IMARC Group, titled “Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, the global hospital acquired disease testing market size reached US$ 10.3 Billion in 2022. Hospital-acquired disease (HAD) tests are used to detect diseases acquired in hospitals and medical clinics, which usually appear after a surgical procedure when the protective skin layer comes into contact with possible threats and causes infection. A hospital-acquired disease testing kit is used to collect samples, test them, and determine which pathogen caused the infection. Most of the diseases generally occur among patients with compromised immunity, primarily due to sub-standard healthcare settings and negligence by hospital staff, or a prevalence of multi-drug resistant organisms (MDROs). Test instruments for hospital-acquired diseases are used by scientists to develop new drugs, culture tissues, engineer gene therapies, make vaccines, and study the toxicity of new drugs. The incubation period can range from 48 hours to 4 days following an admission to an intensive care unit (ICU) or emergency department (ER), so tests are usually conducted after the patient is discharged.
Global Hospital Acquired Disease Testing Market Trends:
The global market is majorly driven by the rising consciousness regarding nosocomial infections among the masses. This can be attributed to the rising influx of patient admissions in the hospitals. In line with this, the rising prevalence of numerous diseases and health conditions, particularly among the geriatric population, is providing an impetus to the market. Additionally, continual technological advancements in numerous testing methods, such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs) and solid phase hybridization, are fueling the market. Moreover, favorable government initiatives for HAD testing and rising stringency in safety regulations are also impacting the market positively. Besides this, the ongoing developments in medical infrastructure due to the growing modernization in the healthcare industry are also creating a positive market outlook. The market is further propelled by considerable growth in the medical tourism industry on the global level. Apart from this, the advent of sophisticated infection detection solutions under molecular diagnostics is creating lucrative growth opportunities in the market. Some of the other factors contributing to the market include the increasing number of healthcare facilities, expanding global population, rising medical expenditure and extensive research and development (R&D) activities conducted by key players. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 27.7 Billion by 2028, exhibiting a CAGR of 17.57% during 2023-2028.
- Based on the indication, the market has been segmented into UTI (Urinary Tract Infection), SSI (Surgical Site Infection), pneumonia, bloodstream infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and others. Urinary tract infection presently represents the largest segment.
- On the geographical front, the market has been segregated into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
- The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation), and Cepheid, Inc.
|Base Year of the Analysis
||Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N A
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800